Gefitinib specifically is a selective tyrosine kinase receptor inhibitor recommended for the therapy of non-small cell lung cancer.
Acting in an identical way to erlotinib (Tarceva), the gefitinib 250 mg tablet selectively targets the mutant proteins in the malignant cells.
Marketed by AZ (AstraZeneca) under the trade name Iressa, gefitinib is available in tablet form, which should be administered by mouth, once in a day with or without food.
Pregnancy/breastfeeding should be avoided while on this therapy.